Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsors and Collaborators: |
Biosynexus Incorporated GlaxoSmithKline |
---|---|
Information provided by: | Biosynexus Incorporated |
ClinicalTrials.gov Identifier: | NCT00631800 |
The purpose of this study is to evaluate the safety (including tolerability), pharmacokinetics, pharmacodynamics and clinical activity of BSYX-A110 administered in a 3-dose regimen on Study Days 0, 7, and 14.
Condition | Intervention | Phase |
---|---|---|
Staphylococcal Sepsis |
Drug: Pagibaximab (formerly BSYX-A110) |
Phase II |
Study Type: | Interventional |
Study Design: | Prevention, Randomized, Double Blind (Subject, Investigator), Placebo Control, Parallel Assignment, Safety/Efficacy Study |
Official Title: | Phase II Randomized, Double Blind, Placebo Controlled, Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity Study in VLBW Neonates of BSYX-A110, for the Prevention of Staphylococcal Infection |
Enrollment: | 88 |
Study Start Date: | May 2003 |
Study Completion Date: | November 2004 |
Primary Completion Date: | March 2004 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
Placebo: Placebo Comparator
Placebo
|
Drug: Pagibaximab (formerly BSYX-A110)
Pagibaximab at 60, 90 mg/kg intravenously at Days 0, 7, 14
|
60 mg/kg: Experimental
60 mg/kg was given on Days 0, 7, 14
|
Drug: Pagibaximab (formerly BSYX-A110)
Pagibaximab at 60, 90 mg/kg intravenously at Days 0, 7, 14
|
90 mg/kg: Experimental
90 mg/kg was given on Days 0, 7, 14
|
Drug: Pagibaximab (formerly BSYX-A110)
Pagibaximab at 60, 90 mg/kg intravenously at Days 0, 7, 14
|
This Phase II study will be a randomized, double blind, placebo controlled study of BSYX-A110 in very low birth weight neonates. A total of 80 infants will be dosed in this study. Participants will receive either BSYX-A110 or placebo, at 60 mg/kg or 90 mg/kg. The Study Drug will be administered at 48-120 hours of life, 7 days after the initial dose, and 14 days after the initial dose for all dose groups.
Ages Eligible for Study: | up to 120 Hours |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
Patients must meet all of the following criteria at the time of first infusion (Day 0):
Multiple gestations:
Exclusion Criteria:
Patients may have none of the following at the first dose:
Severe congenital anomalies or genetic disorders that are likely to be fatal or that may interfere with drug distribution or metabolism, as determined by history and/or physical examination, and including but not limited to:
i. Trisomy 13 ii. Trisomy 18 iii. Hypoplastic Left Heart Syndrome iv. Omphalocele v. Gastroschesis vi. Holoprosencephaly
United States, Texas | |
Texas Children's Hospital/Ben Taub Hospital (Baylor College of Medicine) | |
Houston, Texas, United States, 77030 |
Principal Investigator: | Leonard Weisman, MD | Baylor College of Medicine |
Responsible Party: | Biosynexus Incorporated ( Gerald Fischer, MD, President and CEO ) |
Study ID Numbers: | MAB-N003 |
Study First Received: | February 29, 2008 |
Last Updated: | February 29, 2008 |
ClinicalTrials.gov Identifier: | NCT00631800 |
Health Authority: | United States: Food and Drug Administration |
Staphylococcal Monoclonal antibodies Very Low Birth Weight Infants Prophylaxis |
Antibodies, Monoclonal Systemic Inflammatory Response Syndrome Bacterial Infections Body Weight Birth Weight Staphylococcal Infections |
Antibodies Gram-Positive Bacterial Infections Sepsis Bacteremia Immunoglobulins Inflammation |
Pathologic Processes Infection |